Cochrane Abstracts
alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Alemtuzumab Versus Interferon Beta 1a for Relapsing‐remitting Multiple Sclerosis." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/432006/all/alemtuzumab_versus_interferon_beta_1a_for_relapsing‐remitting_multiple_sclerosis. Accessed 20 September 2024.
Alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/432006/all/alemtuzumab_versus_interferon_beta_1a_for_relapsing‐remitting_multiple_sclerosis. Accessed September 20, 2024.
Alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/432006/all/alemtuzumab_versus_interferon_beta_1a_for_relapsing‐remitting_multiple_sclerosis
Alemtuzumab Versus Interferon Beta 1a for Relapsing‐remitting Multiple Sclerosis [Internet]. In: Cochrane Abstracts. [cited 2024 September 20]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/432006/all/alemtuzumab_versus_interferon_beta_1a_for_relapsing‐remitting_multiple_sclerosis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis
ID - 432006
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/432006/all/alemtuzumab_versus_interferon_beta_1a_for_relapsing‐remitting_multiple_sclerosis
DB - Evidence Central
DP - Unbound Medicine
ER -
